TheEdgeResearch
Home / Stocks / PHAR

Pharming Group N.V. (PHAR)

NASDAQ Healthcare Biotechnology
$11.54 ▼ -5.15%
Market Cap
$816.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.09
52-Wk Range
9.11-21.34
CEO
Kenneth Lynard
Country
NL
Currency
USD

Pharming Group N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Leiden, ZH, NL. The stock last traded at $11.54, down 5.15% on the session, giving a market capitalisation of $816.8M. On trailing twelve-month figures it carries a trailing P/E of 33.70, a net margin of 6.3%. Its beta of 0.09 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
33.70
Price / Sales
2.17
Price / Book
2.93
EV / EBITDA
17.83
Gross margin
84.3%
Operating margin
6.9%
Net margin
6.3%
Return on equity
—
Debt / equity
0.39
Current ratio
3.23
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
407
IPO date
2020-12-23
Headquarters
Leiden, ZH, NL
About Pharming Group N.V.

Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.

Comparable companies

Pharming Group N.V. is most often compared with the following Healthcare names:

BCRXBMRNIONSNTLAPHVSPRQRRCKTSLNSTOK
More research on PHAR
PHAR technical analysis PHAR TheEdge Score Compare against peers
Open full interactive analysis & DCF →